SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!
wentyli
Lv1
100 积分
2022-01-18 加入
最近求助
最近应助
互助留言
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial
6天前
已完结
Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders
7天前
已完结
Obesity and insulin resistance: Pathophysiology and treatment
11天前
已完结
Metabolic Messengers: glucagon-like peptide 1
12天前
已完结
Advances in incretin-based therapeutics for obesity
12天前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
13天前
已完结
After GLP-1, what’s next for weight loss?
27天前
已完结
Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy
1个月前
已完结
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
1个月前
已完结
The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
1个月前
已完结
没有进行任何应助
感谢
6天前
感谢
7天前
感谢
11天前
感谢
12天前
感谢
13天前
感谢
27天前
感谢
1个月前
感谢
1个月前
感谢,感谢
1个月前
感谢,感谢
1个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论